Phase 3Status unknown
Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (HS-25-C-01)
Multi-center,Randomized,Double Blind, Double Dummy,Placebo Controlled, Efficacy and Safety Study of HS-25 in Combination With Atovastatin in Adults With Primary Hypercholesterolemia
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd. (Industry)
- Enrolment
- 720 planned
- Conditions
- Primary Hypercholesterolemia
- Interventions
- HS-25 10mg; HS-25 10mg combination with Atorvastatin; HS-25 20mg combination with Atorvastatin; Atorvastatin 10mg; HS-25 20mg; Placebe of HS-25 and Atorvastatin
- Ages
- adults, older adults
- Registry
- NCT03464682
Full record on ClinicalTrials.gov
From the registry
To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in subjects with LDL-C after a 40-week period of treament.
Primary outcomes
- Percent change of LDL-C
History
Study completion
Primary completion
Last registry update
Registered
Started